Valion Bio Q2 net loss widens to $7.1 million; operating loss deepens to $6.4 million

• Valion Bio posted a GAAP net loss of $7.1 million for Q2 2026, widening from $1.93 million a year earlier.
• GAAP operating loss widened to $6.42 million from $1.68 million, as total operating expenses climbed to $6.42 million from $1.68 million.
• Research and development expense rose to $2.7 million from $655,000, while selling, general and administrative costs increased to $3.72 million from $1.02 million.
• Cash and cash equivalents were $2.1 million at June 30, 2026; cash used in operating activities was $10.29 million for H1 2026.
• Michael K. Handley became CEO in March; the company reported a 200x Entolimod manufacturing scale-up at 50-liter fermentation volume.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-028069), on August 14, 2026, and is solely responsible for the information contained therein.